Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

BACKGROUND: Overexpression of Galectin-3 (Gal-3), a β-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 GAC patients characterised by histologic grade, sub-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Ajani, Jaffer A, Estrella, Jeannelyn S, Chen, Qiongrong, Correa, Arlene M, Ma, Lang, Scott, Ailing W, Jin, Jiankang, Liu, Bin, Xie, Min, Sudo, Kazuki, Shiozaki, Hironori, Badgwell, Brian, Weston, Brian, Lee, Jeffrey H, Bhutani, Manoop S, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Ding, Sheng, Hofstetter, Wayne L, Johnson, Randy L, Bresalier, Robert S, Song, Shumei
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2018
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765229/
https://ncbi.nlm.nih.gov/pubmed/29136404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.388
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares